Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73602635" target="_blank" >RIV/61989592:15110/20:73602635 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/20:00116254 RIV/00216208:11110/20:10416834 RIV/00064190:_____/20:N0000008 RIV/00209805:_____/20:00078442
Result on the web
<a href="https://link.springer.com/article/10.1007%2Fs11523-020-00744-8" target="_blank" >https://link.springer.com/article/10.1007%2Fs11523-020-00744-8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s11523-020-00744-8" target="_blank" >10.1007/s11523-020-00744-8</a>
Alternative languages
Result language
angličtina
Original language name
Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib
Original language description
Background Sarcopenia is common in advanced cancer and correlates with poor performance status, increased risk of treatment-related toxicity, and shortened survival. Inhibitors of the vascular endothelial growth factor pathway have been associated with development or deterioration of sarcopenia. Objective To assess the prevalence and impact of sarcopenia on survival in patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib, a novel, highly potent multikinase inhibitor. Patients and Methods Patients treated with cabozantinib for mRCC progressing on other targeted therapies with available computed tomography (CT) scans acquired at the time of initiation of cabozantinib and on the first restaging were evaluated retrospectively. Muscle mass was assessed based on striated muscle area at the level of the third lumbar vertebra.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Targeted Oncology
ISSN
1776-2596
e-ISSN
—
Volume of the periodical
15
Issue of the periodical within the volume
5
Country of publishing house
FR - FRANCE
Number of pages
7
Pages from-to
673-679
UT code for WoS article
000555352100001
EID of the result in the Scopus database
2-s2.0-85089013138